Aldevron News / James Brown, Ph.D.

Aldevron's Plasmids Used In Cancer Prevention Vaccine Trial

Aldevron client and partner, Calviri, testing vaccine to prevent cancer in trial using 800 dogs

Aldevron has the privilege of working with thousands of clients trying to solve the world’s biggest health challenges and cancer is at the top of the list. Finding a preventative therapy has long been the goal. Our partner, Calviri, is testing a vaccine in a canine trial that could lead to a treatment for humans.

Read More

Aldevron, Nature Technology Corporation team up to offer Nanoplasmids™ for gene therapy manufacturing

Aldevron has announced the immediate availability of NanoplasmidsTM and antibiotic-free RNA-OUT technology for use in gene therapy manufacturing. Through a license agreement with Nature Technology Corporation (NTC), Aldevron can now provide its clients the option of using NTC’s plasmid technology to provide a more efficient system for manufacturing viral vectors used in gene and cell therapy.

Read More

Aldevron announces GMP gene synthesis service to support neoantigen-based oncology research and other applications

Aldevron has added GMP gene synthesis to its array of services. This expanded capability will be used primarily to support Aldevron’s clients who require rapid GMP gene synthesis for novel cancer treatments based on neoantigens. The company noted the service is not suited for routine, research-grade synthesis, for which Aldevron will continue using outside providers.  

Read More

Aldevron announces ready-to-use helper plasmid for AAV manufacturing

New plasmid to reduce cost and timeline for gene therapy manufacturing

Aldevron, the world’s leading contract plasmid manufacturing organization, has announced the immediate availability of an off-the-shelf version of pXX6-80, a common adeno-associated virus (AAV) helper plasmid. The plasmid is designed to reduce the cost of AAV manufacturing and subsequent gene therapy applications, while helping Aldevron’s clients meet regulatory requirements.

Read More